Subdued Growth No Barrier To Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) With Shares Advancing 35%
Mar 06
688319 Share Price Performance
CN¥28.74
20.03 (229.97%)
Price CN¥28.74
Share PriceCN¥28.74
688319 Community Narratives
There are no narratives available yet.
Chengdu Olymvax Biopharmaceuticals Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.098
- Gross Margin
- 95.02%
- Net Profit Margin
- 6.55%
- Debt/Equity Ratio
- 40.8%
Chengdu Olymvax Biopharmaceuticals Inc. Competitors
Snowflake Analysis
About 688319
- Founded
- 2009
- Employees
- 470
- CEO
- WebsiteView website
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use. It offers adsorbed tetanus vaccine; Hib conjugate vaccine; Group A streptococcus vaccine; and AC conjugate vaccine. The company also provides vaccines for haemophilus influenzae type b; group A and C meningococcal; and staphylococcus aureus, which is in Phase 3 clinical trial. In addition, it engages in technology promotion and application services business; biotechnology, R&D, and consulting. The company was founded in 2009 and is based in Chengdu, China.
Market Insight
The number of IPOs and the capital raised this year are on track to outpace the last three years combined. And the thing is, successful IPOs attract more IPOs. Some will be genuine gems, while others, not so much. That’s why this week, we’re digging into the IPO market, and more importantly, how you can improve your odds of spotting a winner.
Continue reading
Chinese Market Performance
- 7 Days: -0.2%
- 3 Months: 15.8%
- 1 Year: 47.8%
- Year to Date: 21.0%
The market has been flat in the last week, however the Energy sector is down 3.2%. As for the longer term, the market has risen 49% in the past 12 months. Earnings are forecast to grow by 26% annually. Market details ›